Wed, February 6, 2013
Tue, February 5, 2013
Mon, February 4, 2013
Sun, February 3, 2013
Sat, February 2, 2013
Fri, February 1, 2013
Thu, January 31, 2013
Wed, January 30, 2013
Tue, January 29, 2013
Mon, January 28, 2013
Sun, January 27, 2013
Sat, January 26, 2013
Fri, January 25, 2013
Thu, January 24, 2013
Wed, January 23, 2013
Tue, January 22, 2013
Mon, January 21, 2013
Fri, January 18, 2013
Thu, January 17, 2013
Wed, January 16, 2013
[ Wed, Jan 16th 2013 ]: Market Wire
30 pm EST
Tue, January 15, 2013
Mon, January 14, 2013

Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating Results and Host Conference Call and Webcast on F


//health-fitness.news-articles.net/content/2013/ .. s-and-host-conference-call-and-webcast-on-f.html
Published in Health and Fitness on by Market Wire   Print publication without navigation



Regeneron to Report Fourth Quarter and Full Year 2012 Financial and Operating... -- TARRYTOWN, N.Y., Jan. 28, 2013 /PRNewswire/ --

TARRYTOWN, N.Y., Jan. 28, 2013 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)today announced that it will report its fourth quarter and full year 2012 financial and operating results on Thursday, February 14, 2013, before the U.S. financial markets open.  The Company will host a conference call and simultaneous webcast at 8:30 AM EST that day.

Conference Call Information

To access this call, dial (888) 660-6127 (U.S.) or (973) 890-8355 (International).  A link to the webcast may be accessed from the 'Events and Presentations' page of Regeneron's website at [ www.regeneron.com ].  A replay of the conference call and webcast will be archived on the Company's website and will be available for 30 days. 

About Regeneron Pharmaceuticals, Inc.

Regeneron is a leading science-based biopharmaceutical company based in Tarrytown, New York that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions.  Regeneron markets medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates in development in other areas of high unmet medical need, including hypercholesterolemia, rheumatoid arthritis, and asthma.  For additional information about the company, please visit [ www.regeneron.com ].

Contact Information:




Michael Aberman, M.D.

Peter Dworkin

Investor Relations

Corporate Communications                               

914-847-7799

914.847.7640                

[ michael.aberman@regeneron.com ]

[ peter.dworkin@regeneron.com ]

 

SOURCE Regeneron Pharmaceuticals, Inc.



RELATED LINKS
[ http://www.regeneron.com ]

Publication Contributing Sources

Publication Sponsors
[ Last Sunday ] - Oceanside Rental Gear